Disclaimer: All stock information on InvestorIntel.com is currently being fed from multiple sources and is updated automatically every 10-minutes. The information on this site is for information purposes only and InvestorIntel Corp. is neither responsible nor liable for the accuracy of this data.
Assuming you aren’t a meme stock or an equity driven by the Reddit army, then you know you’ve told the […]
In a recent InvestorIntel interview, Tracy Weslosky spoke with Brent Willis, President and CEO of Voyageur Pharmaceuticals Ltd. (TSXV: VM) about […]
In a recent InvestorIntel interview, Jack Lifton spoke with Brent Willis, President and CEO of Voyageur Pharmaceuticals Ltd. (TSXV: VM) […]
Voyageur Pharmaceuticals Ltd. is Canadian public company listed on the TSX Venture Exchange under the trading symbol VM. Voyageur is focused on the development of barite and iodine, Active Pharmaceutical Ingredient (API) minerals. The near-term focus is developing barium and iodine radiocontrast pharmaceutical products. Voyageur’s goal is to initially generate near term positive cash flow from operations using third party GMP pharmaceutical manufacturers in Canada and internationally. Ultimately, Voyageur has plans to build all the required infrastructure to become 100% self-sufficient with all manufacturing. Voyageur owns a 100% interest in three barium sulfate (barite) projects including two properties suitable in grade for the industrial barite marketplace, with interests in a potentially high-grade iodine, lithium & bromine brine project located in Utah, USA. Voyageur is moving forward with its business plan of becoming the only fully-integrated company in the radiographic contrast medical field, by controlling all primary input costs under the motto of: "From the Earth to the Bottle"
